Inclusion Criteria:  With newly diagnosed multiple myeloma (NDMM) eligible and non-eligible for a high-dose therapy and autologous stem cell transplantation (HDT-ASCT) who have had a response (defined as CR, VGPR, or PR) to the ongoing SoC induction (1st line) therapy that has been started within 3 months before the inclusion. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at the time of inclusion.  Exclusion Criteria:  With NDMM eligible and non-eligible for a HDT-ASCT who have had SD or PD to the ongoing standard of care (SoC) induction (1st line) therapy that has been started within 3 months before the inclusion. Current, previous (within the last year) or planned (for the next 15-20 months) participation in interventional clinical trial.